Non Small Cell Lung Cancer Clinical Trial
— OPTIMUNELUNGOfficial title:
Integrative Analysis of the Tumor Microenvironment and Optimization of the Immunotherapy Duration in Non-small Cell Lung Cancer Patients (OPTIMUNE-LUNG Study)
Verified date | January 2024 |
Source | Institut Bergonié |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Non-comparative multicentric randomized study to assess long-term benefit of PD-1 inhibition in NSCLC patients who experienced a response between 6 and 12 months after initiation of ICI (immune checkpoint inhibitor PD1/PDL-1 blockade therapy)
Status | Active, not recruiting |
Enrollment | 80 |
Est. completion date | August 2026 |
Est. primary completion date | August 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Histologically or cytologically confirmed non-small cell lung carcinoma (squamous or non squamous). 2. Locally advanced/unresectable or metastatic disease. 3. For non-squamous histology, tumor with no oncogenic addiction: no activating EGFR mutation, no ALK or ROS1 rearrangement, 4. Treatment with ICI (immune checkpoint inhibitor PD1/PDL-1 blockade therapy): 1. in first or second-line treatment as per market authorization. For patients in first line, ICI alone or ICI + chemotherapy, 2. start of ICI treatment 6 to 12 months (+/- 2 weeks) before registration. 5. At least one measurable lesion according to the RECIST v1.1 criteria before ICI treatment onset and confirmed by centralized review (lesion in previously irradiated filed can be considered as measurable if progressive at inclusion according to RECIST v1.1). At least one site of disease must be uni-dimensionally = 10 mm. 6. Patient with objective response according to RECIST v1.1 criteria at 6 months or more and less than 12 months after ICI treatment onset. Response must be confirmed by centralized review 7. At least one lesion that can be biopsied for research purpose. 8. Age = 18. 9. Performance status < 2. 10. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to registration. 11. Patient with a social security in compliance with the French law (Loi Jardé). 12. Patient must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures. 13. Voluntarily signed and dated written informed consent prior to any study specific procedure. Exclusion Criteria: 1. Female who is pregnant or breast-feeding. 2. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study. 3. Hypersensitivity to one of the active substances or to one of the excipients 4. Any contraindication to pursue ICI treatment as per investigator judgement. 5. Previous enrolment in the present study. 6. Individual deprived of liberty or placed under legal guardianship. |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier de la Côte Basque | Bayonne | |
France | Clinique Tivoli Ducos | Bordeaux | |
France | Institut Bergonie | Bordeaux | |
France | Polyclinique Bordeaux Nord Aquitaine | Bordeaux | |
France | Clinique Marzet | Pau |
Lead Sponsor | Collaborator |
---|---|
Institut Bergonié |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of the long-term benefit of PD-1 inhibition in NSCLC patients who experienced a response between 6 and 12 months after initiation of ICI | Long-term benefit will be assessed in terms of progression-free rate (PFR) at 12 months after randomization, for each therapeutic strategy | 12 months | |
Secondary | Assessment of secondary resistance in NSCLC patients who experienced a response to PD1/PDL-1 inhibition | The rate of patients who develop progression (as per RECIST v1.1) due to secondary resistance after obtaining a response to PD1/PDL-1 inhibition, independently for each therapeutic strategy | 12 months | |
Secondary | Duration of response independently for each therapeutic strategy | Duration of response (DoR) defined as the time interval between the first response (complete or partial response as per RECIST v1.1) to the time of the first documentation of disease progression | Throughout the treatment period, an expected average of 12 months | |
Secondary | 1-year progression-free survival, independently for each therapeutic strategy | Progression-free survival (PFS) defined as the time interval between the date of randomization and the date of progression or death, whichever occurs first. Progression will be determined according to RECIST v1.1 | 1 year | |
Secondary | 2-year progression-free survival, independently for each therapeutic strategy | Progression-free survival (PFS) defined as the time interval between the date of randomization and the date of progression or death, whichever occurs first. Progression will be determined according to RECIST v1.1 | 2 years | |
Secondary | 1-year overall survival, independently for each therapeutic strategy | Overall Survival (OS) defined as the time interval between the date of randomization and the date of death (of any cause) | 1 year | |
Secondary | 2-year overall survival, independently for each therapeutic strategy | Overall Survival (OS) defined as the time interval between the date of randomization and the date of death (of any cause) | 2 years | |
Secondary | Safety profile, independently for each therapeutic strategy: Common Terminology Criteria for Adverse Events version 5 | Toxicity graded using the Common Terminology Criteria for Adverse Events version 5 | Throughout the treatment and follow-up period, an expected average of 12 months | |
Secondary | • To describe retreatment for arm B-patients and subsequent systemic therapies for arm A-patients | Number of patients retreated by ICI will be described in Arm B. Similarly, for arm A-patients, number of patients treated by subsequent systemic therapy will be described | Throughout the treatment and follow-up period, an expected average of 12 months | |
Secondary | Tumor immune cells levels | Levels of immune cells in tumor will be measured by immunohistochemistry. | At study onset (randomization) and at progression (throughout the treatment and follow-up period, an average of 12 months) | |
Secondary | Blood cytokines levels | Levels of cytokines in blood will be measured by ELISA | At study onset (randomization) and at progression (throughout the treatment and follow-up period, an average of 12 months) | |
Secondary | Blood lymphocytes levels | Levels of lymphocytes in blood will be measured by flow cytometry | At study onset (randomization) and at progression (throughout the treatment and follow-up period, an average of 12 months) | |
Secondary | Blood kynurenine levels | Levels of kynurenine in blood will be measured by ELISA | At study onset (randomization) and at progression (throughout the treatment and follow-up period, an average of 12 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Completed |
NCT03780010 -
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
|
Phase 1 |